Two Years with COVID-19: The Electronic Frailty Index Identifies High-Risk Patients in the Stockholm GeroCovid Study.


Journal

Gerontology
ISSN: 1423-0003
Titre abrégé: Gerontology
Pays: Switzerland
ID NLM: 7601655

Informations de publication

Date de publication:
2023
Historique:
received: 13 04 2022
accepted: 25 08 2022
medline: 5 4 2023
pubmed: 1 12 2022
entrez: 30 11 2022
Statut: ppublish

Résumé

Frailty, a measure of biological aging, has been linked to worse COVID-19 outcomes. However, as the mortality differs across the COVID-19 waves, it is less clear whether a medical record-based electronic frailty index (eFI) that we have previously developed for older adults could be used for risk stratification in hospitalized COVID-19 patients. The aim of the study was to examine the association of frailty with mortality, readmission, and length of stay in older COVID-19 patients and to compare the predictive accuracy of the eFI to other frailty and comorbidity measures. This was a retrospective cohort study using electronic health records (EHRs) from nine geriatric clinics in Stockholm, Sweden, comprising 3,980 COVID-19 patients (mean age 81.6 years) admitted between March 2020 and March 2022. Frailty was assessed using a 48-item eFI developed for Swedish geriatric patients, the Clinical Frailty Scale, and the Hospital Frailty Risk Score. Comorbidity was measured using the Charlson Comorbidity Index. We analyzed in-hospital mortality and 30-day readmission using logistic regression, 30-day and 6-month mortality using Cox regression, and the length of stay using linear regression. Predictive accuracy of the logistic regression and Cox models was evaluated by area under the receiver operating characteristic curve (AUC) and Harrell's C-statistic, respectively. Across the study period, the in-hospital mortality rate decreased from 13.9% in the first wave to 3.6% in the latest (Omicron) wave. Controlling for age and sex, a 10% increment in the eFI was significantly associated with higher risks of in-hospital mortality (odds ratio = 2.95; 95% confidence interval = 2.42-3.62), 30-day mortality (hazard ratio [HR] = 2.39; 2.08-2.74), 6-month mortality (HR = 2.29; 2.04-2.56), and a longer length of stay (β-coefficient = 2.00; 1.65-2.34) but not with 30-day readmission. The association between the eFI and in-hospital mortality remained robust across the waves, even after the vaccination rollout. Among all measures, the eFI had the best discrimination for in-hospital (AUC = 0.780), 30-day (Harrell's C = 0.733), and 6-month mortality (Harrell's C = 0.719). An eFI based on routinely collected EHRs can be applied in identifying high-risk older COVID-19 patients during the continuing pandemic.

Identifiants

pubmed: 36450240
pii: 000527206
doi: 10.1159/000527206
pmc: PMC9747746
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

396-405

Informations de copyright

© 2022 The Author(s). Published by S. Karger AG, Basel.

Auteurs

Jonathan K L Mak (JKL)

Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden, jonathan.mak@ki.se.

Maria Eriksdotter (M)

Division of Clinical Geriatrics, Department of Neurobiology, Care sciences and Society, Karolinska Institutet, Stockholm, Sweden.
Theme Inflammation and Aging, Karolinska University Hospital, Huddinge, Sweden.

Martin Annetorp (M)

Division of Clinical Geriatrics, Department of Neurobiology, Care sciences and Society, Karolinska Institutet, Stockholm, Sweden.
Theme Inflammation and Aging, Karolinska University Hospital, Huddinge, Sweden.

Ralf Kuja-Halkola (R)

Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.

Laura Kananen (L)

Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
Faculty of Social Sciences (Health Sciences) and Gerontology Research Center (GEREC), University of Tampere, Tampere, Finland.

Anne-Marie Boström (AM)

Theme Inflammation and Aging, Karolinska University Hospital, Huddinge, Sweden.
Division of Nursing, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden.
Research and Development Unit, Stockholms Sjukhem, Stockholm, Sweden.

Miia Kivipelto (M)

Division of Clinical Geriatrics, Department of Neurobiology, Care sciences and Society, Karolinska Institutet, Stockholm, Sweden.
Theme Inflammation and Aging, Karolinska University Hospital, Huddinge, Sweden.

Carina Metzner (C)

Division of Clinical Geriatrics, Department of Neurobiology, Care sciences and Society, Karolinska Institutet, Stockholm, Sweden.
Theme Inflammation and Aging, Karolinska University Hospital, Huddinge, Sweden.

Viktoria Bäck Jerlardtz (V)

Department of Geriatric Medicine, Jakobsbergsgeriatriken, Stockholm, Sweden.

Malin Engström (M)

Department of Geriatric Medicine, Sabbatsbergsgeriatriken, Stockholm, Sweden.

Peter Johnson (P)

Department of Geriatric Medicine, Capio Geriatrik Nacka AB, Nacka, Sweden.

Lars Göran Lundberg (LG)

Department of Geriatric Medicine, Dalengeriatriken Aleris Närsjukvård AB, Stockholm, Sweden.

Elisabet Åkesson (E)

Research and Development Unit, Stockholms Sjukhem, Stockholm, Sweden.
Division of Neurogeriatrics, Department of Neurobiology, Care sciences and Society, Karolinska Institutet, Stockholm, Sweden.

Carina Sühl Öberg (C)

Department of Geriatric Medicine, Handengeriatriken, Aleris Närsjukvård AB, Stockholm, Sweden.

Maria Olsson (M)

Department of Geriatric Medicine, Capio Geriatrik Löwet, Stockholm, Sweden.
Department of Geriatric Medicine, Capio Geriatrik Sollentuna, Stockholm, Sweden.

Tommy Cederholm (T)

Division of Clinical Geriatrics, Department of Neurobiology, Care sciences and Society, Karolinska Institutet, Stockholm, Sweden.
Theme Inflammation and Aging, Karolinska University Hospital, Huddinge, Sweden.
Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden.

Sara Hägg (S)

Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.

Dorota Religa (D)

Division of Clinical Geriatrics, Department of Neurobiology, Care sciences and Society, Karolinska Institutet, Stockholm, Sweden.
Theme Inflammation and Aging, Karolinska University Hospital, Huddinge, Sweden.

Juulia Jylhävä (J)

Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
Faculty of Social Sciences (Health Sciences) and Gerontology Research Center (GEREC), University of Tampere, Tampere, Finland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH